title: Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients.
abstract: OBJECTIVE
  To assess whether spironolactone has beneficial effects on blood pressure (BP), N-terminal propeptide of type III procollagen (PIIINP) and pulse wave velocity (PWV) in hypertensive, type II diabetics.
  
  
  METHODS
  Ten patients with type II diabetes and hypertension were enrolled in a randomized, double-blind crossover study comparing 4 months' treatment with spironolactone and placebo with a 4-week washout phase. BP, PIIINP and carotid-radial PWV were measured at the end of each treatment phase.
  
  
  RESULTS
  Compared with placebo, spironolactone reduced systolic BP by 15.6 +/- 46.1 mmHg (P = 0.005, 95% CI 2.7-28.5 mmHg), PIIINP by 0.6 +/- 0.3 microg l(-1) (P = 0.04, 95% CI 0.02-1.1 microg l(-1)) and PWV by 0.6 +/- 0.2 m s(-1) (P = 0.008, 95% CI 0.18-1.02 m s(-1)).
  
  
  CONCLUSIONS
  Spironolactone is effective at reducing systolic BP and brachial artery stiffness as indicated by PWV. It also reduces PIIINP in type II diabetic patients with hypertension.
authors.affiliation: Division of Medicine and Therapeutics, Ninewells Hospital and Medical School, Dundee, UK. j.i.davies@dundee.ac.uk
authors.forename: J
authors.initials: J
authors.lastname: Davies
authors.forename: A
authors.initials: A
authors.lastname: Gavin
authors.forename: M
authors.initials: M
authors.lastname: Band
authors.forename: A
authors.initials: A
authors.lastname: Morris
authors.forename: A
authors.initials: A
authors.lastname: Struthers
mesh_terms: D000368:Aged; D001783:Blood Flow Velocity / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000378:metabolism*; D011347:Procollagen / Q000378:metabolism*; D011674:Pulse; D013148:Spironolactone / Q000627:therapeutic use*; D014655:Vascular Resistance / Q000187:drug effects
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D010446:Peptide Fragments; D011347:Procollagen; C041876:procollagen Type III-N-terminal peptide; D013148:Spironolactone